Xeris Biopharma Holdings, Inc. XERS Total Cost of Revenue

Total Cost of Revenue at other companies

Eli LillyLLY

$3.27B+33.5%

Corcept TherapeuticsCORT

$4.06M+18.3%

Eton Pharmaceuticals, Inc.ETON

$9.53M+28.4%

Zevra Therapeutics, Inc.ZVRA

$1.53M-87.7%

ANI PharmaceuticalsANIP

$100.16M+34.2%

Rigel PharmaceuticalsRIGL

$4.61M+4.5%

FAQ

What is Xeris Biopharma Holdings, Inc.'s total cost of revenue?

Xeris Biopharma Holdings, Inc. (XERS) reported total cost of revenue of $12.51M in Q2 2026.

How has Xeris Biopharma Holdings, Inc.'s total cost of revenue changed year-over-year?

Xeris Biopharma Holdings, Inc.'s total cost of revenue increased by 5.2% year-over-year, from $11.9M to $12.51M.

What is the long-term trend for Xeris Biopharma Holdings, Inc.'s total cost of revenue?

Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s total cost of revenue has grown at a 33.7% compound annual growth rate (CAGR), from $13.32M to $42.57M.

What does total cost of revenue mean?

The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.